Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
-$0.19 today
- Market cap
- $859.56M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
Volume 0.99M
Average 1.49M
CRVS Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Corvus Pharmaceuticals, Inc.NASDAQ: CRVS
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$14.88M, compared with -$9.92M a year earlier. Trailing-twelve-month operating income was -$47.93M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 4 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -56.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$14.88M-21.8% QoQ
- Last fiscal yearDec 2025
- -$42.97M-56.0% YoY
- LTMMar 2026
- -$47.93M-53.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -49.9% | +100.0% | +149.9 pp |
| 1 year | -56.0% | +100.0% | +156.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (42.97M) USD
- Year-over-year change
- -56.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (42.97M) | -56.0% |
| FY2024 | 2024-12-31 | (27.55M) | -17.7% |
| FY2023 | 2023-12-31 | (23.41M) | +28.1% |
| FY2022 | 2022-12-31 | (32.57M) | +15.7% |
| FY2021 | 2021-12-31 | (38.63M) | — |
Operating Income vs competitors
How CRVS compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -53.5% is the 8th highest of 9, against a peer median of -25.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $30.7M USD | +307.5% | — | 42.3% | |
| LTM Jun 2024 | -$36.99M USD | — | — | 4534.8% | |
| LTM Mar 2026 | -$47.93M USD | -53.5% | — | — | |
| FY2025 | -€53.43M EUR | -3.6% | — | 1916.9% | |
| LTM Mar 2026 | -$63.66M USD | +36.0% | — | 40.5% | |
| LTM Mar 2026 | -$64.66M USD | -279.8% | — | 181.9% | |
| LTM Mar 2026 | -$75.17M USD | -21.6% | — | — | |
| LTM Jun 2026 | -$131.22M USD | -30.2% | — | 240.4% | |
| LTM Mar 2026 | -$169.75M USD | -48.2% | — | 362.1% | |
| LTM Jun 2026 | -$486M USD | -43.8% | — | 415.4% | |
| Peer median (excluding CRVS) | — | -25.9% | — | 301.2% | |
Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 105K |
| Gross Profit | 0 | 0 | 0 | 0 | (105K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 29.12M | 24.47M | 16.53M | 19.39M | 33.72M |
| Selling, General & Admin | 9.52M | 8.1M | 6.88M | 8.16M | 9.25M |
| Operating Expenses | 38.63M | 32.57M | 23.41M | 27.55M | 42.87M |
| Depreciation & Amortization | 460K | 367K | 151K | 85K | 105K |
| EBITDA | (42.77M) | (40.94M) | (26.88M) | (62.21M) | (15.18M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (38.63M) | (32.57M) | (23.41M) | (27.55M) | (42.97M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 654K | 1.58M | 1.82M | 2.51M |
| Interest Expense | 15K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (4.61M) | (8.74M) | (3.62M) | (34.75M) | 27.69M |
| Income Before Tax | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.03) | (0.89) | (0.56) | (1.02) | (0.19) |
| EPS (Diluted) | (1.03) | (0.89) | (0.56) | (1.02) | (0.53) |
| Weighted Avg Shares | 41.85M | 46.55M | 48.03M | 60.99M | 78.96M |
| Weighted Avg Shares (Diluted) | 41.85M | 46.55M | 48.03M | 60.99M | 79.74M |
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
Intrinsic Alpha fair value
Locked
Current Price
$10.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.